Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422767 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT06422767 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 46 participants.
The verdict
NCT06422767, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
Interventions
- DRUG Placebo
- DRUG Bepirovirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06422767
The ClinicalTrials.gov registry entry for NCT06422767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06422767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06422767 about?
NCT06422767 is a clinical study titled "Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers". This study will evaluate the effect of a single dose of bepirovirsen on the QT interval corrected by Fridericia's formula (QTcF) as compared to placebo. The data generated will be used to model the relationship between bepirovirsen concentration and QTcF.
What is the current status of trial NCT06422767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2024-07-18. Estimated completion is 2025-04-28.
What interventions are being tested in trial NCT06422767?
The interventions under investigation include: Placebo (DRUG), Bepirovirsen (DRUG).
Who is sponsoring clinical trial NCT06422767?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.